Compare DOMO & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMO | TLSA |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.7M | 155.3M |
| IPO Year | 2018 | 2017 |
| Metric | DOMO | TLSA |
|---|---|---|
| Price | $3.42 | $1.08 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $10.28 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 199.2K |
| Earning Date | 05-20-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,857,000.00 | N/A |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.84 | $1.04 |
| 52 Week High | $18.49 | $2.60 |
| Indicator | DOMO | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | 39.65 |
| Support Level | $3.32 | N/A |
| Resistance Level | $3.99 | $1.61 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 64.81 | 2.44 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.